Murat Di̇nçer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Murat Di̇nçer has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Bülent Yıldız
Department of Medical Oncology, Faculty of Medicine, Eskisehir Osmangazi University, 26040 Eskisehir, Türkiye
2 shared publications - Ayla Eker Sariboyaci
Eskisehir Osmangazi University
1 shared publication - Bahar Demir Cevizlidere
Eskisehir Osmangazi University
1 shared publication - Deniz Can Guven
Department of Medical Oncology, Hacettepe University Cancer Institute, 06230 Ankara, Turkey
1 shared publication - Duygu Bayır Garbioğlu
Department of Medical Oncology, Faculty of Medicine, Eskisehir Osmangazi University, 26040 Eskisehir, Türkiye
1 shared publication - Emilia Qomi Ekenel
Orta Doğu Teknik Üniversitesi
1 shared publication
Latest Publications
- Open Access
- 29 June 2026
- Published by Hacettepe University - Medical School in Acta Medica
- Vol. 57 (2) , 139-145
The performance of ChatGPT and Google Bard in medical oncology board examination
Objective: Artificial intelligence (AI) is transforming healthcare, and large language models (LLMs) like ChatGPT and Google Bard have shown promise in providing medical information and decision support. The LLMs performed similarly or better than human participants in several board exams. However, their proficiency in complex clinical scenarios, like in oncology board exams, remains unclear. We aimed to assess the performance of three LLMs (ChatGPT 3.5, ChatGPT 4 and Google Bard) on the oncology board examination. Materials and Methods: We utilized a question bank from the Turkish Society of Medical Oncology Board Exam encompassing 290 multiple-choice questions from 2021-2023. ChatGPT 3.5, ChatGPT 4, and Google Bard were asked to answer each question in both Turkish and English, providing explanations and confidence levels with their answers. Results: The overall accuracy of LLMs was 59.3%, 42.8%, 36.2% for ChatGPT4, ChatGPT3.5, and Google Bard, respectively. The accuracy of ChatGPT 4 was significantly higher than that of ChatGPT 3.5 (p<0.001) and Google Bard (p<0.001), while the accuracy of ChatGPT3.5 was higher than that of Google Bard (p<0.001). Only the ChatGPT 4 was proficient in all three examination years (2021-2023). All LLMs performed better on translated questions than original Turkish ones. The LLMs were more accurate in general knowledge than case questions and were more confident in their answers for translated questions. Conclusion: LLMs had moderate success in a medical oncology board exam, with only ChatGPT 4 demonstrating proficiency. The efficacy of LLMs in clinical decision-making requires further development, especially in native languages and complex case interpretations.
- 29 June 2026
- Published by Hacettepe University - Medical School in Acta Medica
- Vol. 57 (2) , 139-145
Open AccessThe performance of ChatGPT and Google Bard in medical oncology board examination
Objective: Artificial intelligence (AI) is transforming healthcare, and large language models (LLMs) like ChatGPT and Google Bard have shown promise in providing medical information and decision support. The LLMs performed similarly or better than human participants in several board exams. However, their proficiency in complex clinical scenarios, like in oncology board exams, remains unclear. We aimed to assess the performance of three LLMs (ChatGPT 3.5, ChatGPT 4 and Google Bard) on the oncology board examination. Materials and Methods: We utilized a question bank from the Turkish Society of Medical Oncology Board Exam encompassing 290 multiple-choice questions from 2021-2023. ChatGPT 3.5, ChatGPT 4, and Google Bard were asked to answer each question in both Turkish and English, providing explanations and confidence levels with their answers. Results: The overall accuracy of LLMs was 59.3%, 42.8%, 36.2% for ChatGPT4, ChatGPT3.5, and Google Bard, respectively. The accuracy of ChatGPT 4 was significantly higher than that of ChatGPT 3.5 (p<0.001) and Google Bard (p<0.001), while the accuracy of ChatGPT3.5 was higher than that of Google Bard (p<0.001). Only the ChatGPT 4 was proficient in all three examination years (2021-2023). All LLMs performed better on translated questions than original Turkish ones. The LLMs were more accurate in general knowledge than case questions and were more confident in their answers for translated questions. Conclusion: LLMs had moderate success in a medical oncology board exam, with only ChatGPT 4 demonstrating proficiency. The efficacy of LLMs in clinical decision-making requires further development, especially in native languages and complex case interpretations.
- Open Access
- 22 June 2024
- Published by Wiley in Cell Biochemistry and Function
- Vol. 42 (4) , e4079
Establishment, culture and characterization of gemcitabine hydrochloride‐resistant human non‐small cell lung carcinoma cell line derived cancer stem cells
Due to their high expression profile of multi‐drug resistance genes, cancer stem cells (CSCs) are the main source of drug resistance. The aim of this study was to establish a gemcitabine‐hydrochloride‐resistant (rt) human non‐small cell lung cancer (hNSCLC) cell line and their CSC line to be used as disease models in various cancer studies. In the first phase of study, a gemcitabine hydrochloride‐rt hNSCLC line cells was produced by making them rt through periodic exposure to gemcitabine hydrochloride. This acquired gemcitabine‐hydrochloride‐rt hNSCLC cell line was characterized for resistance. Subsequently, a CSC population with a CD326 + CD133 + CD44+ phenotypes was immunoselectively isolated from gemcitabine hydrochloride‐rt hNSCLCs purified from a single cell by colony forming technology. This rt CSC line was characterized for both resistance and stemness. Rt and non‐rt CSCs were analyzed and compared with each other in terms of immunophenotyping the expression profiles of ALDH1, CD90, ABCG2, CD44 and MDR1, which are CSC specific markers, of demonstrating mitotic capacity with growth curve analysis and of their ability to form tumor spheroids in three different 3D cultures. The results of this study demonstrated for the first time the successful generation of both gemcitabine‐hydrochloride‐rt hNSCLC cells and CSCs derived from gemcitabine‐hydrochloride‐rt hNSCLC cells. It was also shown that isolated and characterized rt CSCs could proliferate and form tumor spheres in vitro using three different 3D in vitro techniques. It was shown that the cell surface markers CD326, CD133 and CD44 can serve as an antibody panel for CSCs.
- 22 June 2024
- Published by Wiley in Cell Biochemistry and Function
- Vol. 42 (4) , e4079
Open AccessEstablishment, culture and characterization of gemcitabine hydrochloride‐resistant human non‐small cell lung carcinoma cell line derived cancer stem cells
Due to their high expression profile of multi‐drug resistance genes, cancer stem cells (CSCs) are the main source of drug resistance. The aim of this study was to establish a gemcitabine‐hydrochloride‐resistant (rt) human non‐small cell lung cancer (hNSCLC) cell line and their CSC line to be used as disease models in various cancer studies. In the first phase of study, a gemcitabine hydrochloride‐rt hNSCLC line cells was produced by making them rt through periodic exposure to gemcitabine hydrochloride. This acquired gemcitabine‐hydrochloride‐rt hNSCLC cell line was characterized for resistance. Subsequently, a CSC population with a CD326 + CD133 + CD44+ phenotypes was immunoselectively isolated from gemcitabine hydrochloride‐rt hNSCLCs purified from a single cell by colony forming technology. This rt CSC line was characterized for both resistance and stemness. Rt and non‐rt CSCs were analyzed and compared with each other in terms of immunophenotyping the expression profiles of ALDH1, CD90, ABCG2, CD44 and MDR1, which are CSC specific markers, of demonstrating mitotic capacity with growth curve analysis and of their ability to form tumor spheroids in three different 3D cultures. The results of this study demonstrated for the first time the successful generation of both gemcitabine‐hydrochloride‐rt hNSCLC cells and CSCs derived from gemcitabine‐hydrochloride‐rt hNSCLC cells. It was also shown that isolated and characterized rt CSCs could proliferate and form tumor spheres in vitro using three different 3D in vitro techniques. It was shown that the cell surface markers CD326, CD133 and CD44 can serve as an antibody panel for CSCs.
- Open Access
- 31 December 2023
- Published by Bulent Evcevit University in Batı Karadeniz Tıp Dergisi
- Vol. 7 (3) , 344-349
Evaluation of Solid Tumor Patients Presenting with Denovo Bone Marrow Metastasis
Aim: Although solid tumors are known to metastasize to the bone marrow, it is rare to be diagnosed with bone marrow involvement. In our study, we aimed to contribute to the literature by evaluating the treatment results and follow-up processes of different solid tumors metastatic to bone marrow in denovo. Material and Methods: We retrospectively analyzed 28 patients who underwent bone marrow biopsy with a prediagnosis of hematologic malignancy and were diagnosed with carcinoma metastasis. Clinicopathologic features, antitumor treatments, treatment-related hematologic toxicities and factors affecting survival were evaluated. Results: Of the 28 patients included in the study, 14 (50.0%) were female and 14 (50.0%) were male. The median age of the patients was 62 years (28-82). Eight patients (28.6%) were diagnosed with breast (28.6%), six with gastric (21.4%), four with lung (14.3%), two each with colon and prostate ca (7.1%), and the primary tumor site could not be determined in six patients (21.4%). Progression was observed in four (40.0%) of the 10 patients with the first series of treatment, three (30.0%) patients had stable response and three (30.0%) patients had partial response. The median progression-free survival time was 130 days (3-494 days) in patients who received first line treatment. The median overall survival time was 26 days (0-1183 days). Thrombocytopenia (p<0.05), hypofibrinogenemia (p<0.05), and poor performance score (p<0.05) were associated with lower survival. Conclusion: Solid tumor patients diagnosed with denovo bone marrow metastases have a very poor prognosis. Additional poor prognostic factors in these patients include thrombocytopenia, hypofibrinogenemia, poor performance status. Accurate and rapid diagnosis of the primary solid tumor through bone marrow biopsy can help establish an appropriate treatment approach focused on the primary carcinoma Amaç: Solid tümörlerin kemik iliği metastazı yaptığı bilinmesine rağmen kemik iliği tutulumu ile tanı almaları nadir görülmektedir. Çalışmamızda denovo kemik iliği metastatik farklı solid tümörlerin tedavi sonuçları ve takip süreçlerini değerlendirerek literatüre katkı sağlamak amaçlanmıştır Gereç ve Yöntemler: Hematolojik malignite ön tanısı ile kemik iliği biyopsisi yapılan ve karsinom metastazı tanısı alan 28 hasta retrospektif olarak incelendi. Hastaların klinikopatolojik özellikleri, aldıkları antitümör tedaviler, tedavi ilişkili hematolojik toksisiteleri ve sağkalımlarına etki eden faktörler değerlendirildi. Bulgular: Çalışmaya dahil edilen 28 hastanın 14'ü (%50,0) kadın, 14'ü (%50,0) erkekti. Hastaların median yaşı 62 (28-82) idi. Hastaların sekizi (%28,6) meme, altısı mide (%21,4), dördü akciğer (%14,3), ikişer (%7,1) tanesi de kolon ve prostat ca (%7,1) tanısı almış olup altı hastanın (%21,4) primer tümör bölgesi belirlenememiştir. Tedavi verilen 10 hastanın dört tanesinde (%40,0) ilk seri tedavi ile progresyon gözlenmiş olup, üç hastada (%30,0) stabil, üç (%30,0) hastada parsiyel tedavi yanıtı elde edilmiştir. İlk seri tedavi alan hastalarda progresyonsuz sağkalım süresi median 130 gün (3-494 gün) gözlenmiştir. Hastaların median genel sağkalım süresi 26 gündür (0-1183 gün). Trombositopeni (p<0,05), hipofibrinojenemi (p<0,05) ve kötü performans skoru (p<0,05) daha düşük sağkalımla ilişkili bulunmuştur. Sonuç: Denovo kemik iliği metastazı ile tanı alan solid tümor hastalarının prognozu çok kötüdür. Bu hastalardaki ek kötü prognostik faktörler arasında trombositopeni, hipofibrinojenemi, kötü performans durumu sayılabilir. Kemik iliği biyopsisi yoluyla primer solid tümörün doğru ve hızlı teşhisi ile primer karsinom üzerine odaklanan uygun bir tedavi yaklaşımının oluşturulmasına yardımcı olabilir
- 31 December 2023
- Published by Bulent Evcevit University in Batı Karadeniz Tıp Dergisi
- Vol. 7 (3) , 344-349
Open AccessEvaluation of Solid Tumor Patients Presenting with Denovo Bone Marrow Metastasis
Aim: Although solid tumors are known to metastasize to the bone marrow, it is rare to be diagnosed with bone marrow involvement. In our study, we aimed to contribute to the literature by evaluating the treatment results and follow-up processes of different solid tumors metastatic to bone marrow in denovo. Material and Methods: We retrospectively analyzed 28 patients who underwent bone marrow biopsy with a prediagnosis of hematologic malignancy and were diagnosed with carcinoma metastasis. Clinicopathologic features, antitumor treatments, treatment-related hematologic toxicities and factors affecting survival were evaluated. Results: Of the 28 patients included in the study, 14 (50.0%) were female and 14 (50.0%) were male. The median age of the patients was 62 years (28-82). Eight patients (28.6%) were diagnosed with breast (28.6%), six with gastric (21.4%), four with lung (14.3%), two each with colon and prostate ca (7.1%), and the primary tumor site could not be determined in six patients (21.4%). Progression was observed in four (40.0%) of the 10 patients with the first series of treatment, three (30.0%) patients had stable response and three (30.0%) patients had partial response. The median progression-free survival time was 130 days (3-494 days) in patients who received first line treatment. The median overall survival time was 26 days (0-1183 days). Thrombocytopenia (p<0.05), hypofibrinogenemia (p<0.05), and poor performance score (p<0.05) were associated with lower survival. Conclusion: Solid tumor patients diagnosed with denovo bone marrow metastases have a very poor prognosis. Additional poor prognostic factors in these patients include thrombocytopenia, hypofibrinogenemia, poor performance status. Accurate and rapid diagnosis of the primary solid tumor through bone marrow biopsy can help establish an appropriate treatment approach focused on the primary carcinoma Amaç: Solid tümörlerin kemik iliği metastazı yaptığı bilinmesine rağmen kemik iliği tutulumu ile tanı almaları nadir görülmektedir. Çalışmamızda denovo kemik iliği metastatik farklı solid tümörlerin tedavi sonuçları ve takip süreçlerini değerlendirerek literatüre katkı sağlamak amaçlanmıştır Gereç ve Yöntemler: Hematolojik malignite ön tanısı ile kemik iliği biyopsisi yapılan ve karsinom metastazı tanısı alan 28 hasta retrospektif olarak incelendi. Hastaların klinikopatolojik özellikleri, aldıkları antitümör tedaviler, tedavi ilişkili hematolojik toksisiteleri ve sağkalımlarına etki eden faktörler değerlendirildi. Bulgular: Çalışmaya dahil edilen 28 hastanın 14'ü (%50,0) kadın, 14'ü (%50,0) erkekti. Hastaların median yaşı 62 (28-82) idi. Hastaların sekizi (%28,6) meme, altısı mide (%21,4), dördü akciğer (%14,3), ikişer (%7,1) tanesi de kolon ve prostat ca (%7,1) tanısı almış olup altı hastanın (%21,4) primer tümör bölgesi belirlenememiştir. Tedavi verilen 10 hastanın dört tanesinde (%40,0) ilk seri tedavi ile progresyon gözlenmiş olup, üç hastada (%30,0) stabil, üç (%30,0) hastada parsiyel tedavi yanıtı elde edilmiştir. İlk seri tedavi alan hastalarda progresyonsuz sağkalım süresi median 130 gün (3-494 gün) gözlenmiştir. Hastaların median genel sağkalım süresi 26 gündür (0-1183 gün). Trombositopeni (p<0,05), hipofibrinojenemi (p<0,05) ve kötü performans skoru (p<0,05) daha düşük sağkalımla ilişkili bulunmuştur. Sonuç: Denovo kemik iliği metastazı ile tanı alan solid tümor hastalarının prognozu çok kötüdür. Bu hastalardaki ek kötü prognostik faktörler arasında trombositopeni, hipofibrinojenemi, kötü performans durumu sayılabilir. Kemik iliği biyopsisi yoluyla primer solid tümörün doğru ve hızlı teşhisi ile primer karsinom üzerine odaklanan uygun bir tedavi yaklaşımının oluşturulmasına yardımcı olabilir